Doctors review Real-World results for key lung cancer drug
NCT ID NCT07213076
Summary
This study looked back at the medical records of 350 Australian patients with advanced lung cancer who had a specific genetic change (EGFR mutation). Researchers analyzed how long patients stayed on a targeted drug called osimertinib, and how it affected their survival, when it was used as either a first or second treatment. The goal was to understand real-world treatment patterns and outcomes, not to test a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Melbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.